Get the Stockscreener App
0.6293
3.04%
-0.0197
Fibrobiologics Inc stock is traded at $0.6293, with a volume of 313.15K.
It is down -3.04% in the last 24 hours and down -27.67% over the past month.
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
See More
Previous Close:
$0.649
Open:
$0.67
24h Volume:
313.15K
Relative Volume:
0.94
Market Cap:
$35.81M
Revenue:
-
Net Income/Loss:
$-17.78M
P/E Ratio:
-1.1458
EPS:
-0.5492
Net Cash Flow:
$-10.52M
1W Performance:
+2.83%
1M Performance:
-27.67%
6M Performance:
-66.53%
1Y Performance:
-87.02%
1-Day Range:
$0.6138
$0.6797
1-Week Range:
$0.5833
$0.6797
52-Week Range:
$0.5833
$5.62
Fibrobiologics Inc Stock (FBLG) Company Profile
Name
Fibrobiologics Inc
Sector
Industry
Phone
281-671-5150
Address
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
0.6293 | 35.81M | 0 | -17.78M | -10.52M | -0.5492 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-24 | Initiated | H.C. Wainwright | Buy |
| Sep-24-24 | Initiated | Maxim Group | Buy |
Fibrobiologics Inc Stock (FBLG) Latest News
FibroBiologics (NASDAQ:FBLG) vs. Neumora Therapeutics (NASDAQ:NMRA) Head to Head Contrast - Defense World
Brag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Fall River Herald News
FibroBiologics to Present at the Advanced Wound Care Summit USA - GlobeNewswire
FibroBiologics Reveals Breakthrough Diabetic Foot Ulcer Treatment Ahead of Phase 1/2 Trial - Stock Titan
FibroBiologics Inc. (NASDAQ:FBLG) Receives Consensus Rating of “Buy” from Brokerages - Defense World
D. Boral Capital Reaffirms “Buy” Rating for FibroBiologics (NASDAQ:FBLG) - Defense World
Fibrobiologics Confirms Ability to Manufacture Cybrocell for Degenerative Disc Disease and Cartilage Repair Programs from Existing Cywc628 Master Cell Bank - MarketScreener
FibroBiologics announces advancement in its cartilage repair program - TipRanks
FibroBiologics Confirms Ability to Manufacture CybroCell™ - GlobeNewswire
Breakthrough: FibroBiologics Achieves Major Cost-Saving Milestone in Degenerative Disc Disease Treatment Development - Stock Titan
FibroBiologics Webinar: A Crossroads for Pipeline Progress and IP Dominance in Cell Therapy - AInvest
FibroBiologics, Inc. Announces Investor Webinar on Innovative Fibroblast-Based Cell Therapy Platform - Nasdaq
FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10 - GlobeNewswire
FibroBiologics to Reveal Next-Gen Cell Therapy Platform: 275+ Patents Target Billion-Dollar Markets - Stock Titan
Disruptive Innovation and Clinical Breakthroughs: Fathom Holdings and FibroBiologics Lead the Charge - AInvest
Fathom Holdings and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Bluefield Daily Telegraph
FibroBiologics, Inc.(NasdaqCM: FBLG) dropped from Russell 2000 Index - MarketScreener
FibroBiologics Inc (NASDAQ: FBLG) Has Great Upside Potential - Stocksregister
Fibrobiologics closes third $5 mln tranche of $25 mln financing - MarketScreener
FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing - GlobeNewswire
FibroBiologics Raises $25M to Launch Breakthrough Diabetic Foot Ulcer Treatment Trial - Stock Titan
FibroBiologics to Present Company Update and Research Advances at BIO International Convention 2025 - Nasdaq
FibroBiologics to Present at the BIO International Convention 2025 - GlobeNewswire
Clinical Trial Alert: FibroBiologics Unveils Groundbreaking Fibroblast Treatment for Chronic Disease at BIO 2025 - Stock Titan
FibroBiologics, Inc. (NASDAQ:FBLG) Receives Consensus Rating of “Buy” from Brokerages - Defense World
FibroBiologics names new CFO after going public last year - The Business Journals
FibroBiologics appoints new CFO amid clinical trials By Investing.com - Investing.com South Africa
FibroBiologics, Inc. Appoints Jason D. Davis as Chief Financial Officer, Effective June 9, 2025 - MarketScreener
FibroBiologics appoints Jason Davis as CFO - TipRanks
FibroBiologics Appoints Jason Davis As CFO - Nasdaq
FibroBiologics appoints new CFO amid clinical trials - Investing.com Australia
FibroBiologics, Inc. Appoints Jason D. Davis as Chief Financial Officer to Drive Growth and Clinical Development - Nasdaq
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer - GlobeNewswire
FibroBiologics Taps Former Virax IPO Leader as CFO Ahead of Critical Clinical Trials - Stock Titan
Jane Street Group LLC Acquires 49,222 Shares of FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
Top Executive Makes Bold Move with Major Stock Purchase in FibroBiologics! - TipRanks
FibroBiologics, Inc. (NASDAQ:FBLG) Receives $13.00 Consensus PT from Analysts - Defense World
FBLG: Poster Presentation Shows Potential for Fibroblast Therapy in Psoriasis - Research Tree
FBLG: Poster Presentation Shows Potential for Fibroblast Therapy in Psoriasis… - Zacks Small Cap Research
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting - GlobeNewswire
D. Boral Capital Reiterates Buy Rating for FibroBiologics (NASDAQ:FBLG) - Defense World
FibroBiologics Presents Research on Human Dermal Fibroblast Spheroids for Psoriasis Therapy at SID Annual Meeting - Nasdaq
Revolutionary Fibroblast Treatment Shows Promise for Long-lasting Psoriasis Relief, New Data Reveals - Stock Titan
Raymond James Financial Inc. Takes $37,000 Position in FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
FibroBiologics Reports First Quarter 2025 Financial Results And Provides Corporate Update - marketscreener.com
FibroBiologics, Inc. Reports First Quarter 2025 Financial Results and Operational Milestones - Nasdaq
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
FibroBiologics Earnings: Net Loss Drops 41%, Clinical Trial Launch Set for Breakthrough Wound Treatment - Stock Titan
FibroBiologics, Inc. SEC 10-Q Report - TradingView
FibroBiologics (FBLG) Projected to Post Earnings on Tuesday - Defense World
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - CytoDyn Inc.
Fibrobiologics Inc Stock (FBLG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fibrobiologics Inc Stock (FBLG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| O'HEERON PETE | Chief Executive Officer |
Aug 12 '24 |
Buy |
1.91 |
8,500 |
16,269 |
6,056,647 |
| Khoja Hamid | Chief Scientific Officer |
Aug 12 '24 |
Buy |
1.90 |
10,000 |
19,000 |
11,250 |
2.10%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):